OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)

MLA

Michael P. Whyte, et al. “OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH).” Journal of the Endocrine Society, vol. 3, Apr. 2019. EBSCOhost, https://doi.org/10.1210/js.2019-or13-2.

APA

Michael P. Whyte, Javier San Martin, Chao-Yin Chen, Meng Mao, Hae Il Cheong, Leanne M Ward, Jill H. Simmons, Noriyuki Namba, Erik A. Imel, Alison Skrinar, Raja Padidela, Ola Nilsson, Craig F Munns, Francis H. Glorieux, & Anthony A. Portale. (2019). OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH). Journal of the Endocrine Society, 3. https://doi.org/10.1210/js.2019-or13-2

Chicago

Michael P. Whyte, Javier San Martin, Chao-Yin Chen, Meng Mao, Hae Il Cheong, Leanne M Ward, Jill H. Simmons, et al. 2019. “OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH).” Journal of the Endocrine Society 3 (April). doi:10.1210/js.2019-or13-2.